Analyzing Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) and Structure Therapeutics (NASDAQ:GPCR)

Structure Therapeutics (NASDAQ:GPCR) and Hansa Biopharma AB (publ) (OTCMKTS:HNSBF) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability and analyst recommendations.

Valuation and Earnings

This table compares Structure Therapeutics and Hansa Biopharma AB (publ)”s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Structure Therapeutics	N/A	N/A	-$89.62 million	($0.77)	-48.90
Hansa Biopharma AB (publ)	N/A	N/A	N/A	($0.87)	-3.38

Structure Therapeutics is trading at a lower price-to-earnings ratio than Hansa Biopharma AB (publ), indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Structure Therapeutics and Hansa Biopharma AB (publ)’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Structure Therapeutics	N/A	-20.12%	-19.11%
Hansa Biopharma AB (publ)	N/A	N/A	N/A

Analyst Ratings

This is a summary of recent ratings and recommmendations for Structure Therapeutics and Hansa Biopharma AB (publ), as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Structure Therapeutics	0	0	7	0	3.00
Hansa Biopharma AB (publ)	0	0	0	0	N/A

Structure Therapeutics currently has a consensus target price of $84.63, indicating a potential upside of 124.65%. Given Structure Therapeutics’ higher probable upside, equities research analysts clearly believe Structure Therapeutics is more favorable than Hansa Biopharma AB (publ).

Institutional & Insider Ownership

91.8% of Structure Therapeutics shares are owned by institutional investors. 9.4% of Structure Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Structure Therapeutics beats Hansa Biopharma AB (publ) on 5 of the 8 factors compared between the two stocks.

About Structure Therapeutics

Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company’s lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity. It is also developing oral small molecule therapeutics targeting other GPCRs for the treatment of pulmonary and cardiovascular diseases, including ANPA-0073, a biased agonist for apelin receptor, a GPCR that has been implicated in idiopathic pulmonary fibrosis (IPF); and LTSE-2578, an investigational oral small molecule lysophosphatidic acid 1 receptor antagonist for the treatment of IPF and PPF. The company was formerly known as ShouTi Inc. Structure Therapeutics Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

About Hansa Biopharma AB (publ)

Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Europe and the United States. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a collaboration agreement with Sarepta Therapeutics to assess imlifidase as a pre-treatment in limb-girdle muscular dystrophy (LGMD) and duchenne muscular dystrophy (DMD); AskBio to evaluate imlifidase as a pre-treatment in pompe disease; and research and development collaboration agreement with Genethon to evaluate the safety and efficacy of imlifidase as pre-treatment to gene therapy in Crigler-Najjar syndrome patients with anti-AAV antibodies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.